Pimobendan, the active ingredient in Cardisure®, is a positive inotrope and vasodilator. It enhances myocardial contractility and dilates blood vessels, reducing cardiac workload and improving blood flow. Cardisure® is available in flavoured tablets to facilitate administration.
| Indications | Treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy. |
|---|---|
| Contraindications | Not for use in cases of hypertrophic cardiomyopathy or conditions where increased cardiac output is not possible due to functional or anatomical reasons (e.g., aortic stenosis). Use with caution in dogs with severe hepatic impairment. Safety during pregnancy and lactation has not been established; use only if the potential benefit justifies the risk. |
| Dosage | Dosage for Dogs: Administer orally at a dose range of 0.2 mg to 0.6 mg pimobendan per kg body weight per day. The preferred daily dose is 0.5 mg/kg, divided into two doses (0.25 mg/kg each), given approximately 12 hours apart. Administer on an empty stomach, at least one hour before feeding, to enhance absorption. The maintenance dose should be individually adjusted by the veterinarian based on the severity of the disease. Dosage for Cats: The safety and efficacy of Cardisure® in cats have not been established; therefore, its use in feline patients is not recommended. |
| Storage | Store below 25°C in a cool, dry place. Keep out of reach of children and other animals. Use any divided tablets within 3 days. |
Be the first to review “Cardisure®”
Reviews
There are no reviews yet.